BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3305969)

  • 1. Severe hepatotoxicity from Escherichia coli L-asparaginase.
    Jenkins R; Perlin E
    J Natl Med Assoc; 1987 Jul; 79(7):775, 779. PubMed ID: 3305969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia.
    Leventhal BG; Skeel RT; Yankee RA; Henderson ES
    Cancer Chemother Rep; 1970 Feb; 54(1):47-51. PubMed ID: 4945997
    [No Abstract]   [Full Text] [Related]  

  • 3. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.
    Haskell CM; Canellos GP; Leventhal BG; Carbone PP; Block JB; Serpick AA; Selawry OS
    N Engl J Med; 1969 Nov; 281(19):1028-34. PubMed ID: 4898857
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.
    Al-Nawakil C; Willems L; Mauprivez C; Laffy B; Benm'rad M; Tamburini J; Fontaine H; Sogni P; Terris B; Bouscary D; Moachon L
    Leuk Lymphoma; 2014 Jul; 55(7):1670-4. PubMed ID: 24090500
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical experience with L-asparaginase.
    Carbone PP; Haskell CM; Leventhal BG; Block JB; Selawry OS
    Recent Results Cancer Res; 1970; 33():236-43. PubMed ID: 4949163
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.
    Ettinger LJ; Biener R; Finklestein JZ; Kamalakar P; Jones GR; Avramis VI; Holcenberg JS
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):155-9. PubMed ID: 3859930
    [No Abstract]   [Full Text] [Related]  

  • 7. [Transient diabetes mellitus during L-asparaginase therapy].
    Zoltán K; István V
    Orv Hetil; 1975 Jul; 116(28):1644-5. PubMed ID: 1056586
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of acute leukemia with the L-asparaginase. Preliminary results based on 84 cases].
    Bernard J; Jacquillat C; Boiron M; Weil M; Bussel A; Larrieu MJ; Delobel J; Goguel A; Levy D; Tanzer J
    Presse Med (1893); 1970 Jan; 78(4):161-6. PubMed ID: 5264814
    [No Abstract]   [Full Text] [Related]  

  • 9. Intermediate dose methotrexate and sequential L-asparaginase for treatment of refractory acute lymphocytic leukaemia.
    Shetty PA; Kurkure PA; Dasgupta A
    Indian J Cancer; 1984; 21(1):45-9. PubMed ID: 6595214
    [No Abstract]   [Full Text] [Related]  

  • 10. [Induction of remission by sequential treatment with cytosine arabinoside (araC/high dose) and L-asparaginase].
    Martín-Aragonés G; Sanz MA; Martínez JA; Rafecas FJ; Gomis F; Lorenzo I; Sanz G; Marty ML
    Sangre (Barc); 1985; 30(1):15-21. PubMed ID: 3859023
    [No Abstract]   [Full Text] [Related]  

  • 11. Clotting complications of L-asparaginase therapy in children with ALL.
    Cappellato MG; Rosolen A; Zanesco L; Girolami A
    Blut; 1986 Jun; 52(6):377-8. PubMed ID: 3459563
    [No Abstract]   [Full Text] [Related]  

  • 12. [Asparaginase, 1969].
    Boiron M; Levy D
    Pathol Biol (Paris); 1969 Dec; 17(23):1129-32. PubMed ID: 4908018
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antineoplastic effect of L-asparaginase].
    Opolski A
    Postepy Hig Med Dosw; 1981; 35(2):177-87. PubMed ID: 7038650
    [No Abstract]   [Full Text] [Related]  

  • 14. [Asparaginase, leukemia and cancer].
    Levy D; Boiron M
    Bull Cancer; 1969; 56(4):365-74. PubMed ID: 4928248
    [No Abstract]   [Full Text] [Related]  

  • 15. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
    Clavell LA; Gelber RD; Cohen HJ; Hitchcock-Bryan S; Cassady JR; Tarbell NJ; Blattner SR; Tantravahi R; Leavitt P; Sallan SE
    N Engl J Med; 1986 Sep; 315(11):657-63. PubMed ID: 2943992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial sonograms to detect pancreatitis in children receiving L-asparaginase.
    Nguyen DL; Wilson DA; Engelman ED; Sexauer CL; Nitschke R
    South Med J; 1987 Sep; 80(9):1133-6. PubMed ID: 3306944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Asparaginase-induced fulminating liver dysfunction.
    Okamura A; Nishimura M; Sanada Y; Yakushijin K; Matsuoka H; Yamamoto K; Minami H
    Int J Hematol; 2013 Jul; 98(1):6-7. PubMed ID: 23702916
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia].
    Jürgens H; Schwamborn D; Körholz D; Wahn V; Göbel U
    Klin Padiatr; 1988; 200(3):184-9. PubMed ID: 3210651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some clinical observations on the treatment with L-asparaginase of the acute leukemias.
    Marmont AM; Damasio EE
    Recent Results Cancer Res; 1970; 33():296-315. PubMed ID: 4949165
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.